[go: up one dir, main page]

MX2014000515A - Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido. - Google Patents

Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.

Info

Publication number
MX2014000515A
MX2014000515A MX2014000515A MX2014000515A MX2014000515A MX 2014000515 A MX2014000515 A MX 2014000515A MX 2014000515 A MX2014000515 A MX 2014000515A MX 2014000515 A MX2014000515 A MX 2014000515A MX 2014000515 A MX2014000515 A MX 2014000515A
Authority
MX
Mexico
Prior art keywords
ketoaldehyde
gamma
hypertension
skavengers
methods
Prior art date
Application number
MX2014000515A
Other languages
English (en)
Other versions
MX383365B (es
Inventor
L Jackson Roberts
Venkataraman Amarnath
David G Harrison
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MX2014000515A publication Critical patent/MX2014000515A/es
Publication of MX383365B publication Critical patent/MX383365B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un método para tratar al menos uno de inflamación, psoriasis, y/o hipertensión el cual comprende administrar a un paciente en necesidad del mismo una cantidad efectiva de eliminación de gama-cetoaldehídos de un compuesto eliminador de gamma-cetoaldehídos.
MX2014000515A 2011-07-12 2012-07-12 Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos. MX383365B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506848P 2011-07-12 2011-07-12
PCT/US2012/046549 WO2013010034A2 (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Publications (2)

Publication Number Publication Date
MX2014000515A true MX2014000515A (es) 2014-03-27
MX383365B MX383365B (es) 2025-03-13

Family

ID=47506934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000515A MX383365B (es) 2011-07-12 2012-07-12 Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.

Country Status (13)

Country Link
US (4) US10975033B2 (es)
EP (1) EP2731597B1 (es)
JP (1) JP6280033B2 (es)
KR (2) KR20140050661A (es)
CN (2) CN103796648B (es)
AU (1) AU2012281061B2 (es)
BR (1) BR112014000810A8 (es)
CA (1) CA2844150C (es)
ES (1) ES2970814T3 (es)
HU (1) HUE065757T2 (es)
MX (1) MX383365B (es)
PL (1) PL2731597T3 (es)
WO (1) WO2013010034A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130018478A (ko) * 2011-08-09 2013-02-25 주식회사 엘지화학 신규한 구조의 이차전지 팩
US11400103B2 (en) 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
US10166248B1 (en) 2015-12-21 2019-01-01 Vanderbilt University Methods of preventing platelet activation
US11633370B2 (en) 2016-07-06 2023-04-25 Vanderbilt University Use of scavengers of reactive gamma-ketoaldehydes to extend cell lifespan and healthspan
CA3030149A1 (en) * 2016-07-07 2018-01-11 Vanderbilt University Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers
AU2017324935B2 (en) * 2016-09-06 2021-10-21 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
EA202190602A3 (ru) 2016-09-07 2021-11-30 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
US20190314302A1 (en) * 2016-11-15 2019-10-17 Vanderbilt University Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
WO2018201074A1 (en) 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
CA3074736A1 (en) * 2017-09-05 2019-03-14 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法
US20200197323A1 (en) * 2018-12-21 2020-06-25 Vanderbilt University Methods for suppressing accumulation of reflux-induced protein adducts
EP4097115A4 (en) * 2020-01-27 2024-03-13 Vanderbilt University ANTI-MITOCHONDRIAL ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF
CN118652245B (zh) * 2024-08-21 2024-11-12 首都医科大学附属北京儿童医院 一种化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740439A (en) * 1968-06-24 1973-06-19 Ciba Geigy Corp Treating hypertension with beta-aminoalkane carboxylic acids
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US4123537A (en) * 1977-05-26 1978-10-31 Merck & Co., Inc. 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
AU5659796A (en) 1995-05-19 1996-11-29 Kissei Pharmaceutical Co. Ltd. 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors
US6043259A (en) 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
ATE333868T1 (de) * 2000-11-02 2006-08-15 Univ South Carolina Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7705054B1 (en) * 2004-10-20 2010-04-27 Vanderbilt University Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases
CA2738070C (en) * 2007-10-05 2018-03-20 Index Pharmaceuticals Ab Novel compounds for the treatment or alleviation of edema, and methods for their use
KR100973343B1 (ko) * 2008-02-01 2010-07-30 롯데칠성음료주식회사 기호성이 우수한 혼합차 조성물 및 그 제조방법
CN101305759B (zh) * 2008-06-19 2011-09-07 成都大学 一种苦荞保健茶及其制备方法
CN101843671A (zh) * 2009-03-25 2010-09-29 王文祥 苦荞托毒丸及其制备方法
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
CN101606986A (zh) * 2009-07-29 2009-12-23 李钢 一种具有降糖作用的组合物及其药物

Also Published As

Publication number Publication date
CN103796648A (zh) 2014-05-14
WO2013010034A3 (en) 2013-03-28
MX383365B (es) 2025-03-13
US20210261508A1 (en) 2021-08-26
WO2013010034A2 (en) 2013-01-17
US20140256774A1 (en) 2014-09-11
CA2844150A1 (en) 2013-01-17
CA2844150C (en) 2019-09-03
CN103796648B (zh) 2019-10-25
ES2970814T3 (es) 2024-05-30
JP6280033B2 (ja) 2018-02-14
CN111494352A (zh) 2020-08-07
HUE065757T2 (hu) 2024-06-28
KR102050700B1 (ko) 2019-11-29
US10975033B2 (en) 2021-04-13
US20250214939A1 (en) 2025-07-03
EP2731597B1 (en) 2023-12-20
JP2014524918A (ja) 2014-09-25
US20250034093A1 (en) 2025-01-30
PL2731597T3 (pl) 2024-04-29
EP2731597A4 (en) 2015-04-08
KR20190069607A (ko) 2019-06-19
EP2731597C0 (en) 2023-12-20
KR20140050661A (ko) 2014-04-29
BR112014000810A2 (pt) 2017-06-13
AU2012281061A1 (en) 2014-02-20
BR112014000810A8 (pt) 2022-11-29
AU2012281061B2 (en) 2017-08-03
EP2731597A2 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX373925B (es) Tratamiento del cancer con inhibidores de tor cinasa.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
MX2021015735A (es) Composiciones de nucleasa terapeuticas y metodos.
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
AR092475A1 (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
MX2015003416A (es) Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer.
AR089993A1 (es) Macrociclos peptidomimeticos
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2017004580A (es) Combinaciones de auristatina sinergica.
MX2013011932A (es) Inhibidores de parp para el tratamiento de cipn.
IN2014CN04634A (es)
MX357510B (es) Metodos para tratar ataques de gota.
EA201490800A1 (ru) Способ ингибирования деубиквитинирующей активности
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
UY34070A (es) Método y composición para tratamiento de semillas.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
TR201900665T4 (tr) Diyabetik nefropatinin tedavi yöntemi.
MX2015007164A (es) Uso de estracto de fenogreco para mejorar la libido femenina.
EA201491581A1 (ru) Везикулярные композиции